Certificate of Attendance
Complete the event evaluation to provide feedback and claim your CME credits. Your Certificate of Attendance will be sent to you by email.
If you also need a detailed record of attendance, please make sure to fill in the session evaluation and contact us at [email protected] in order to obtain the document.
Evaluation is only possible for registered attendees and All-Access Pass holders until July 24th.
Registered attendee (onsite and Congress registrants online)
Evaluation will be available from Monday, 29th April noon.
All Access Pass holders
If you have an All Access Pass, please click on the below button to get access to the event evaluation. You can then use the buttons above for your evaluation. Once you have access you can use the regular evaluation links.
Session Evaluation
Session evaluation is open for regular congress attendees and for already signed in All access pass holders.
IOFC 1 – Essentials of oncology (12:00 – 13:20)
Evaluate
IOFC 2 – Lung cancer and lung metastases (13:20 – 14:25)
Evaluate
IOFC 3 – Primary liver cancer and liver metastases (15:00 – 16:05)
Evaluate
IOFC 4 – Renal cell carcinoma (16:05 – 17:10)
Evaluate
IOFC 5 – Clinical practice in IO (17:10 – 17:50)
Evaluate
CF 111 – Combination strategies in the management of HCC (08:30 – 10:00)
Evaluate
CF 112 – Cancer as a chronic disease (08:30 – 10:00)
Evaluate
HDT-TA 11.1 – Tumour ablation: cold based ablation (08:30 – 10:00)
Evaluate
CF 121 – Immuno oncology: on the delicate interaction of local treatment and systemic immunologic effects (10:30 – 12:00)
Evaluate
CF 122 – Bone metastases: multidisciplinary management (10:30 – 12:00)
Evaluate
HDT-TA 12.1 – Tumour ablation: heat based ablation (10:30 – 12:00)
Evaluate
SED 12.2 – Safe sedation application during IR procedures (basic) (10:30 – 12:00)
Evaluate
SED 13.1 – Safe sedation application during IR procedures (basic) (12:30 – 14:00)
Evaluate
CF 142 – Ask me anything (15:00 – 16:30)
Evaluate
CF 143 – Meet the PI: upcoming research (15:00 – 16:30)
Evaluate
HDT-TA 14.1 – Tumour ablation: non thermal ablation (15:00 – 16:30)
Evaluate
SED 14.2 – Safe sedation application during IR procedures (advanced) (15:00 – 16:30)
Evaluate
TB 141 – Why an IO should be on the tumour board: HCC (15:00 – 16:30)
Evaluate
BC 153 – Kidney and adrenal: renal ablation basics 1 (17:00 – 19:00)
Evaluate
CF 151 – Intrahepatic cholangiocarcinoma: what IRs need to know? (17:00 – 18:30)
Evaluate
CF 152 – Selecting my best first case: why, when, how (17:00 – 18:30)
Evaluate
HDT-TA 15.1 – Tumour ablation: planning, robotics, monitoring and assessment for ablation (17:00 – 18:30)
Evaluate
CF 211 – Colorectal cancer liver metastases (08:30 – 10:00)
Evaluate
CF 212 – Paediatric IO: a practical approach (08:30 – 10:00)
Evaluate
CF 213 – Pain and gain: communication skills (08:30 – 10:00)
Evaluate
HDT-TA 21.1 – Tumour ablation: heat based ablation (08:30 – 10:00)
Evaluate
SED 21.2 – Safe sedation application during IR procedures (basic) (08:30 – 10:00)
Evaluate
HDT-TA 22.1 – Tumour ablation: planning, robotics, monitoring and assessment for ablation (10:30 – 12:00)
Evaluate
HL 221 – Honorary Lecture (10:30 – 11:15)
Evaluate
SED 22.2 – Safe sedation application during IR procedures (advanced) (10:30 – 12:00)
Evaluate
SP 222 – Best at ECIO: incoming evidence for liver tumours (11:15 – 12:00)
Evaluate
SED 23.1 – Safe sedation application during IR procedures (Propofol) (12:30 – 14:00)
Evaluate
CF 242 – Non-small cell lung cancer in 2024 (15:00 – 16:30)
Evaluate
EM 241 – ECIO meets ESTRO: collaboration is strength (15:00 – 16:30)
Evaluate
HDT- RE 24.2 – Radioembolization: dosimetry and administration systems (15:00 – 17:00)
Evaluate
HDT-TA 24.1 – Tumour ablation: cold based ablation (15:00 – 16:30)
Evaluate
BC 253 – Kidney and adrenal: renal ablation basics 2 (17:00 – 19:00)
Evaluate
CF 252 – Clinical studies and interventional oncology (17:00 – 18:30)
Evaluate
HDT-TA 25.1 – Tumour ablation: non thermal ablation (17:00 – 18:30)
Evaluate
TB 251 – Why an IO should be on the tumour board: lung (17:00 – 18:30)
Evaluate
CF 311 – Open debates in modern HCC treatment (08:30 – 10:00)
Evaluate
CF 312 – MSK IO: ablate, palliate and protect (08:30 – 10:00)
Evaluate
HDT- RE 31.2 – Radioembolization: dosimetry and administration systems (08:30 – 10:30)
Evaluate
HDT-TA 31.1 – Tumour ablation: planning, robotics, monitoring and assessment for ablation (08:30 – 10:00)
Evaluate
IO 313 – Improving access to interventional oncology (08:30 – 10:00)
Evaluate
CF 322 – Artificial intelligence for interventional oncology (10:30 – 12:00)
Evaluate
HDT-MSK 32.2 – Musculoskeletal oncologic interventions (10:30 – 12:00)
Evaluate
HDT-TA 32.1 – Tumour ablation: non thermal ablation (10:30 – 12:00)
Evaluate
SP 323 – Technical developments and clinical results in the treatment of liver tumours (10:30 – 12:00)
Evaluate
TB 321 – Why an IO should be on the tumour board: renal cancer (10:30 – 12:00)
Evaluate
CF 341 – Breast cancer: new scenarios for an old disease (15:00 – 16:30)
Evaluate
CF 343 – Targeting tumours and assessing the results of treatment (15:00 – 16:30)
Evaluate
EM 342 – ECIO meets ESOT: interventional oncology & transplant oncology – evolving fields in cancer care (15:00 – 16:30)
Evaluate
HDT-MSK 34.2 – Musculoskeletal oncologic interventions (15:00 – 16:30)
Evaluate
HDT-TA 34.1 – Tumour ablation: heat based ablation (15:00 – 16:30)
Evaluate
BC 353 – Kidney and adrenal: adrenal ablation (17:00 – 19:00)
Evaluate
HDT-TA 35.1 – Tumour ablation: cold based ablation (17:00 – 18:30)
Evaluate
SP 352 – Extrahepatic application for IO: revisiting the old and embracing the new (17:00 – 18:30)
Evaluate
VL 351 – How I do it – video learning (17:00 – 18:30)
Evaluate